Key regions: France, India, United Kingdom, South Korea, Japan
The Multiple Sclerosis Drugs market in Sudan has been showing significant development in recent years.
Customer preferences: Patients suffering from Multiple Sclerosis (MS) in Sudan, like in other parts of the world, prefer drugs that can effectively alleviate their symptoms and improve their quality of life. They tend to opt for drugs that have been approved by regulatory authorities and are easily accessible.
Trends in the market: The Multiple Sclerosis Drugs market in Sudan has been growing steadily in recent years. This growth can be attributed to the increasing prevalence of MS in the country, as well as the rising awareness of the disease among healthcare professionals and the general public. Additionally, the introduction of new drugs and treatment options has also contributed to the growth of the market.
Local special circumstances: Sudan, like many other African countries, faces several challenges in terms of healthcare infrastructure and access to medicines. The country has a shortage of trained healthcare professionals, and many patients have limited access to healthcare facilities. Additionally, the country has been facing political instability and economic challenges, which have also impacted the healthcare sector.
Underlying macroeconomic factors: The Multiple Sclerosis Drugs market in Sudan is influenced by several macroeconomic factors. The country has been facing economic challenges, including high inflation rates and a shortage of foreign currency, which have impacted the affordability and availability of medicines. Additionally, the country has a weak regulatory environment, which has led to the proliferation of counterfeit drugs in the market.In conclusion, the Multiple Sclerosis Drugs market in Sudan has been growing steadily in recent years, driven by the increasing prevalence of MS and the introduction of new drugs and treatment options. However, the market is also influenced by several challenges, including a shortage of healthcare professionals, limited access to healthcare facilities, and economic and regulatory challenges.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
